The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer
Pharmacological Research · 2026
DOI: 10.1016/j.phrs.2026.108347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Research, 2026. Verfasst von Mengwei Li und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, Chi…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Membrane Proteins, Intracellular Signaling Peptides and Proteins. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Health Commission, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Small cell lung cancer (SCLC) is an aggressive malignancy with limited effective therapeutic options. DLL3-targeted CAR-T therapy shows promising anti-tumor potential but is often restricted by T-cell exhaustion, which impairs its long-term efficacy. In the present study, we found that golidocitinib, a highly selective JAK1 inhibitor, induces apoptosis in SCLC cells in vitro via inhibiting STAT3 phosphorylation and regulating apoptosis‑associated genes. It also reduced the expression of exhaustion markers in anti-DLL3 CAR-T cells, promoted the formation of memory T cell phenotypes, and enhanced CAR-T cell persistence both in vitro and in vivo. When combined with anti-DLL3 CAR-T therapy, golidocitinib significantly augmented anti-tumor efficacy in both in vitro cytotoxicity assays and in vivo models, without obvious organ toxicity. These findings collectively demonstrate the dual anti-tumor effects of golidocitinib, thus providing a novel and promising strategy for SCLC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Jia…
- Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
- Department of Pulmonary and Critical Care Medicine, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225001, China.
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Health Commission
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Li, M., Zhang, Y., Li, F., Xia, Y., Wang, W., Li, J., Du, H., Tan, R., Qiang, H., Wang, Y., Cao, S., Huang, L., Wu, E., Yang, Y., Zhang, B., Yang, X., Zhou, Y., Zhang, C., & Zhong, H. (2026). The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer. Pharmacological Research. https://doi.org/10.1016/j.phrs.2026.108347
Vancouver
Li M, Zhang Y, Li F, Xia Y, Wang W, Li J, et al. The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer. Pharmacological Research. 2026. doi:10.1016/j.phrs.2026.108347
BibTeX
@article{Li2026,
author = {Li, Mengwei and Zhang, Yao and Li, Fangqi and Xia, Yuchen and Wang, Wanting and Li, Jingwen and Du, Huawei and Tan, Ruiting and Qiang, Huiping and Wang, Yue and Cao, Shuhui and Huang, Litang and Wu, Erpeng and Yang, Yu and Zhang, Bo and Yang, Xuanming and Zhou, Yan and Zhang, Chi and Zhong, Hua},
title = {The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer},
journal = {Pharmacological Research},
year = {2026},
doi = {10.1016/j.phrs.2026.108347}
}
EUVIMED